<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362789</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457ADE03</org_study_id>
    <nct_id>NCT02362789</nct_id>
  </id_info>
  <brief_title>Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers</brief_title>
  <acronym>PSORITUS</acronym>
  <official_title>Exploratory Study on the Kinetics of Psoriasis Symptoms, Pruritus Intensity and Lesional Biomarkers in Patients With Moderate to Severe Plaque-type Psoriasis Treated With Subcutaneous Secukinumab (300 mg) During a 16 Week Open-label run-in Phase Followed by a 16 Week Randomized, Double-blind, Placebo-controlled Withdrawal Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and
      lesional biomarkers during 16 weeks of treatment with 300 mg secukinumab in patients with
      moderate to severe psoriasis and a high pruritus involvement at baseline. For patients who
      achieve extensive remission defined as a PASI response of 98-100%, the kinetics of psoriasis
      and pruritus symptoms will be further explored during a randomized withdrawal phase of 16
      weeks. Biopsies will be taken to investigate lesional biomarkers related to the pathogenesis
      of pruritus in psoriasis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pruritus intensity VAS</measure>
    <time_frame>32 weeks</time_frame>
    <description>To demonstrate that secukinumab has superior efficacy compared to placebo on the pruritus intensity VAS with a recall period of 24 hours (as part of the Patients Global Assessment of Chronic Pruritus, PGA-CP) measured at week 32 in patients with moderate to severe psoriasis.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Absolute PASI and PASI 50/75/90/100 response</measure>
    <time_frame>at weeks 2, 4, 8, 12, 16, 20, 24, 28 and 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients achieving extensive remission defined as PASI reduction by 98-100% vs. baseline</measure>
    <time_frame>at week 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>IGA mod 2011 and IGA mod 2011 0/1-response</measure>
    <time_frame>at weeks 2, 4, 8, 12, 16, 20, 24, 28 and 32.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>DLQI</measure>
    <time_frame>at weeks 2, 4, 8, 12, 16, 20, 24, 28 and 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Scaling, redness and induration of index lesions</measure>
    <time_frame>at weeks 16 and 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Global Assessment of Chronic Pruritus (PGA-CP)</measure>
    <time_frame>at weeks 2, 4, 8, 12, 16, 20, 24, 28 and 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pruritus-specific quality of life (ItchyQoL)</measure>
    <time_frame>at weeks 2, 4, 8, 12, 16, 20, 24, 28 and 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient Benefit Index of Pruritus (PBI-P)</measure>
    <time_frame>at weeks 2, 4, 8, 12, 16, 20, 24, 28 and 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Itch (VAS) at index lesions</measure>
    <time_frame>at weeks 16 and 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers from Skin Biopsies</measure>
    <time_frame>at weeks 16 and 32</time_frame>
    <description>Histology of skin biopsies to determine the number and distribution of inflammatory cells Immunohistochemistry of PGP 9.5 to assess neurite outgrowth
In a subgroup:
Immunohistochemistry of markers of inflammation and pruritus Analysis of differential gene expression levels (RNA) by microarray and verification of candidates by RT-qPCR Analysis of differential protein expression levels by protein microarray and verification of candidates by multiplex assay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>300 mg secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization occurs at week 16 and only for patients with extensive remission. All other patients complete the study at week 16. All patients receive 300 mg secukinumab at weeks at weeks 0, 1, 2, 3, 4, 8, 12. Patients randomized to 300 mg secukinumab at week 16, receive secukinumab at weeks 16, 20, 24, 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab followed by placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomization occurs at week 16 and only for patients with extensive remission. All other patients complete the study at week 16. All patients receive 300 mg secukinumab at weeks at weeks 0, 1, 2, 3, 4, 8, 12. Patients randomized to placebo at week 16, receive placebo at weeks 16, 20, 24, 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab 300 mg</intervention_name>
    <arm_group_label>300 mg secukinumab</arm_group_label>
    <arm_group_label>Secukinumab followed by placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic moderate to severe plaque type psoriasis as diagnosed by a qualified physician
             at least 6 months prior to baseline and with a PASI score &gt; 10 at baseline.

          -  Psoriasis patients with pruritus intensity of â‰¥ 30 on a 100-point VAS, with a recall
             period of 24h as part of the PGA-CP, both, at screening and at baseline.

        Key Exclusion Criteria:

          -  Underlying conditions other than psoriasis which in the opinion of the investigator
             currently cause or influence pruritus of the skin (e.g. drug induced pruritus, renal
             insufficiency, diabetes).

          -  Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and
             guttate) at screening or study start.

          -  Ongoing use of prohibited psoriasis and non-psoriasis treatments. Washout periods have
             to be adhered to. If the use of any of the prohibited treatments is required, then the
             subject may not be included into the study.

          -  Pregnancy, breast feeding or inadequate contraception (if necessary)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dippoldiswalde-Schmiedeberg</city>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45883</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabruck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Selters</city>
        <zip>56242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 12, 2017</submitted>
    <returned>December 4, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

